Harmonet (Ethinylestradiol, Gestodene)

Harmonet is indicated for the prevention of pregnancy in women of reproductive age who choose an oral hormonal method.

• Primary contraceptive use: regular daily dosing to inhibit ovulation.
• Management of menstrual cycle irregularities when combined with contraception.
• May be prescribed for acne improvement associated with hormonal imbalance (off‑label in some regions).
• Provides cycle control and reduces the risk of ovarian cyst formation.
• Can be used as part of a combined hormone regimen after childbirth or abortion, following medical guidance.

Like other combined oral contraceptives, Harmonet may cause a range of side effects that vary in frequency and severity.

Common

• Nausea or mild stomach upset, especially when treatment is initiated.
• Breast tenderness or enlargement.
• Headache or mild migraine episodes.
• Spotting or breakthrough bleeding during the first few cycles.
• Weight fluctuations or fluid retention, often mild and transient.
• Mood changes, including irritability or mild depressive symptoms.

Serious

• Deep vein thrombosis, pulmonary embolism, or other thromboembolic events.
• Severe allergic reaction such as rash, itching, swelling of the face or throat, or difficulty breathing.
• Liver dysfunction indicated by jaundice, dark urine, or severe abdominal pain.

Before starting Harmonet, certain health considerations should be reviewed to ensure safe use and to minimise risks.

• History of thromboembolic disorders, such as deep‑vein thrombosis or pulmonary embolism.
• Current or past cardiovascular disease, including hypertension, stroke, or myocardial infarction.
• Smoking, especially in women over 35 years of age.
• Liver disease or impaired liver function.
• Migraines with aura or severe headache disorders.
• Pregnancy or suspected pregnancy; the product should not be used during pregnancy.
• Breastfeeding women should consult a healthcare professional before using Harmonet.

Harmonet can interact with other medicines, which may alter its effectiveness or increase the risk of adverse events.

Avoid

• Anticoagulants such as warfarin, where hormonal contraception may affect clotting parameters.
• Certain anticonvulsants (e.g., carbamazepine, phenytoin) that can reduce oral contraceptive efficacy.

Use with caution

• Antibiotics like rifampicin that may lower hormone levels.
• Herbal supplements containing St. John’s wort, which can induce hepatic enzymes.
• Antiretroviral drugs (e.g., protease inhibitors) that may require monitoring of contraceptive reliability.
• SSRIs such as fluoxetine may increase the risk of breakthrough bleeding.
• Diuretics may increase the risk of electrolyte imbalance when combined with hormonal contraceptives.